We want our research to improve the lives of patients.
Our scientific work is translational, the patient is the origin and the end of the path of our scientific projects.
As the Clinic's research center, we address clinical problems with a multidisciplinary approach in order to propose the most effective treatment for each patient.
At the forefront of research
Genomics
We generate genomic information from biological samples for precision medicine.
DNA and RNA therapy
We research genetic information to treat diseases and improve people's health.
Immunotherapy
Moléculas inmunorreguladoras y estrategias de vacunación muy prometedoras contra el cáncer.
Molecular Therapies
Design of new molecular therapies to meet unmet medical needs.
Flow cytometry
Novel and highly sensitive techniques for cellular diagnostics in clinical and research settings.
We develop pharmaceuticals that become solutions
Strategic alliances with important companies that encourage us to continue developing our research work
Gene therapy for the treatment of neurological diseases
Therapy to correct mutations associated with Parkinson's disease and other parkinsonisms or movement disorders.
Gene therapy for the treatment of rare diseases
Gene therapy aimed at the treatment of alterations in the ATP7B gene, whose mutation causes its accumulation in the liver and other tissues causing different diseases.
CARDIOPATCH
Regenerative medicine
Solution for myocardial infarction patients by means of a "smart patch" capable of regenerating their cardiac lesion.
Our researchers dream of curing diseases
Behind every discovery there is a story, researchers who have a vision and work to achieve our goal.
Rubén Pío
Solid Tumor Program Researcher
"We are in the era of personalized or precision oncology, according to which each patient is assigned a treatment on an individualized basis, based on the genetic characteristics of his or her tumor.
Ana Patiño
Pediatric Solid Tumor Researcher
"We now have the ability to do these massive genetic studies quickly and affordably, so we should not limit ourselves to the "usual suspect" genes.
We should be a bit more ambitious in genetic analysis, extending it to all genes whose clinical relevance is known.
Luis Montuenga
Solid Tumors Program Researcher
"Despite the great advances made in recent decades in prevention, early diagnosis and treatment, long-term survival is much lower than in other types of cancer.
This situation has led the scientific community to develop personalized therapies that can block the biological alteration of each patient or stimulate their immune system against the tumor.
Gloria Aseguinozala
Gene Therapy Program Researcher
"We advance the molecular understanding of the human genome to develop efficient and safe gene therapy vectors to identify new therapeutic targets and new treatments for severe diseases that currently lack satisfactory treatment.
Maite Huarte
Gene Therapy Program Researcher
"In recent years there has been a major shift in our understanding of genome regulation. This will help in the development of better therapies and diagnostics for this disease.
For this we combine the application of genomics, epigenomics, molecular biology techniques with the analysis of patient samples.
Financing entities
Large companies and entities that are committed and help us so that we can carry out our research activity.
Collaborative Network
Strategic partners
